DNA Polymerase θ (POLQ), His-Tag, SUMO-Tag Recombinant

Only %1 left
Catalog #
101945
As low as $450 *

Cat # Size Price*

Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant human DNA polymerase θ (Theta), also known as POLQ, encompassing amino acids 1792 to 2590. This construct contains an N-terminal His-tag (6xHis) followed by a thrombin cleavage site and a SUMO-tag. This protein was affinity purified.

Synonyms
DNA polymerase theta, DNA polymerase eta, POLQ, POLH
Product Info
Storage and Usage
Citations
Species
Human
Construct
DNA Polymerase θ (His-Th-SUMO-1792-2590)
Host Species/Expression System
E. coli
Purity

≥80%

Format

Aqueous buffer solution

Formulation

40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol

MW
103 kDa
Amino Acids
1792-2590
Genbank #
NM_199420.4
UniProt #
O75417
Tag(s)
N-terminal His-Tag
Background

Polymerases are the enzymes responsible for synthesizing nucleic acids. DNA Polymerase θ, also known as DNA polymerase subunit theta, POLQ, belongs to the Family A of DNA polymerases. In addition to its DNA polymerase activity, it acts on the theta-mediated end joining (TMEJ), which classifies it as a specialized polymerase. TMEJ is a DNA repair mode that is prone to errors, and in addition to DNA polymerase θ it involves PARP1 (poly polymerase 1) and DNA ligase III. Inhibition of DNA polymerase θ in cells containing a homologous recombination (HR) deficiency, as in BRCA (breast cancer type 1/2 susceptibility protein) deficient cells, is synthetic lethal. Therefore, polymerase θ inhibitors are promising candidates for the treatment of HR-deficient cancers or in combination with HR inhibitors such as  PARP inhibitors. Further development of DNA polymerase θ inhibitors will bring new therapy options to cancer patients.